[1] |
Puzianowska⁃Kuźnicka M, Owczarz M, Wieczorowska⁃Tobis K, et al. Interleukin⁃6 and C⁃reactive protein, successful aging, and mortality: the PolSenior study[J]. Immun Ageing, 2016,13:21. doi: 10.1186/s12979⁃016⁃0076⁃x.
|
[2] |
Ye L, Mauro TM, Dang E, et al. Topical applications of an emollient reduce circulating pro⁃inflammatory cytokine levels in chronically aged humans: a pilot clinical study[J]. J Eur Acad Dermatol Venereol, 2019,33(11):2197⁃2201. doi: 10.1111/jdv. 15540.
|
[3] |
Giovannini S, Onder G, Liperoti R, et al. Interleukin⁃6, C⁃reactive protein, and tumor necrosis factor⁃alpha as predictors of mortality in frail, community⁃living elderly individuals[J]. J Am Geriatr Soc, 2011,59(9):1679⁃1685. doi: 10.1111/j.1532⁃5415. 2011.03570.x.
|
[4] |
Nouvenne A, Ticinesi A, Lauretani F, et al. The prognostic value of high⁃sensitivity C⁃reactive protein and prealbumin for short⁃term mortality in acutely hospitalized multimorbid elderly patients: a prospective Cohort study[J]. J Nutr Health Aging, 2016,20(4):462⁃468. doi: 10.1007/s12603⁃015⁃0626⁃5.
|
[5] |
Kerkhof P, Khamaganova I. Sex⁃specific cardiovascular comorbidities with associations in dermatologic and rheumatic disorders[J]. Adv Exp Med Biol, 2018,1065:489⁃509. doi: 10. 1007/978⁃3⁃319⁃77932⁃4_30.
|
[6] |
Brunner PM, Silverberg JI, Guttman⁃Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder[J]. J Invest Dermatol, 2017,137(1):18⁃25. doi: 10. 1016/j.jid.2016.08.022.
|
[7] |
Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows[J]. Front Immunol, 2018,9:1668. doi: 10.3389/fimmu.2018.01668.
|
[8] |
Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all⁃cause mortality among diverse chronic inflammatory disorders[J]. Heart, 2017,103(23):1867⁃1873. doi: 10.1136/heartjnl⁃2017⁃311214.
|
[9] |
Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty[J]. Nat Rev Cardiol, 2018,15(9):505⁃522. doi: 10.1038/s41569⁃018⁃0064⁃2.
|
[10] |
Zhang C, Wang Y, Wang D, et al. NSAID exposure and risk of Alzheimer′s disease: an updated meta⁃analysis from cohort studies[J]. Front Aging Neurosci, 2018,10:83. doi: 10.3389/fnagi. 2018.00083.
|
[11] |
Millington G, Collins A, Lovell CR, et al. British association of dermatologists′ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018[J]. Br J Dermatol, 2018,178(1):34⁃60. doi: 10. 1111/bjd.16117.
|
[12] |
Kikuchi K, Kobayashi H, Hirao T, et al. Improvement of mild inflammatory changes of the facial skin induced by winter environment with daily applications of a moisturizing cream. A half⁃side test of biophysical skin parameters, cytokine expression pattern and the formation of cornified envelope[J]. Dermatology, 2003,207(3):269⁃275. doi: 10.1159/000073089.
|
[13] |
Jang H, Matsuda A, Jung K, et al. Skin pH is the master switch of kallikrein 5⁃mediated skin barrier destruction in a murine atopic dermatitis model[J]. J Invest Dermatol, 2016,136(1):127⁃135. doi: 10.1038/JID.2015.363.
|
[14] |
Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis⁃like lesions through PAR2⁃mediated thymic stromal lymphopoietin expression in Netherton syndrome[J]. J Exp Med, 2009,206(5):1135⁃1147. doi: 10.1084/jem.20082242.
|
[15] |
Sakai T, Hatano Y, Matsuda⁃Hirose H, et al. Combined benefits of a PAR2 inhibitor and stratum corneum acidification for murine atopic dermatitis[J]. J Invest Dermatol, 2016,136(2):538⁃541. doi: 10.1016/j.jid.2015.11.011.
|
[16] |
Hu L, Mauro TM, Dang E, et al. Epidermal dysfunction leads to an age⁃associated increase in levels of serum inflammatory cytokines[J]. J Invest Dermatol, 2017,137(6):1277⁃1285. doi: 10.1016/j.jid.2017.01.007.
|